Expert Point of View: Rebecca A. Miksad, MD, MPH


Get Permission

Rebecca A. Miksad, MD, MPH

Rebecca A. Miksad, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Physician-Investigator at Beth Israel Deaconess Medical Center, Boston, who discussed the paper by Fine et al at the Gastrointestinal Cancers Symposium, said, “the study reports that a range of neuroendocrine tumor types responded to the capecitabine/temozolomide regimen studied. Prospective randomized, controlled data are needed to confirm these findings.” ■

Disclosure: Dr. Miksad reported no potential conflicts of interest.


Related Articles

For Progressive Neuroendocrine Tumors, Clinical Benefit Is High With Capecitabine Plus Temozolomide

In an interim analysis of a phase II trial, 97% of patients with progressive metastatic neuroendocrine tumors achieved clinical benefit with the combination of capecitabine and temozolomide (CAPTEM). The results were reported at the 2014 Gastrointestinal Cancers Symposium by Robert L. Fine, MD,...


Advertisement

Advertisement



Advertisement